The most useful questions to ask doctor about tirzepatide are the ones that uncover whether it fits your health, your medicines, and the next few months of your life. A complete medication list and a clear history of thyroid cancer in the family, pancreatitis, gallbladder trouble, kidney health, diabetes, pregnancy, digestion, eating disorders, other weight medicines, and planned surgery give the provider what they need. They're not looking for perfect answers. They're looking for the full picture.

Questions to ask doctor about tirzepatide: your history

1. Has anyone in my family had medullary thyroid carcinoma or MEN 2?

Medullary thyroid carcinoma (MTC) is a rare thyroid cancer. MEN 2 is an inherited condition that raises the risk of MTC. The current Zepbound label carries a boxed warning after thyroid C-cell tumors occurred in rats; it isn't known whether that finding applies to people. A personal or family history of MTC, or MEN 2, is a contraindication, meaning the branded medicine shouldn't be used.

2. Have I ever had pancreatitis?

Pancreatitis is inflammation of the pancreas. The label warns that cases have occurred with tirzepatide and other GLP-1 medicines. As of September 9, 2026, the day this article was written, a review published in the June 2026 issue of Pancreatology found confirmed pancreatitis was rare across 19 randomized trials, affecting about 2 in 1,000 participants, with no clear dose pattern. A past episode still matters because the provider needs to understand its cause and recurrence risk.

3. Have I had gallstones, gallbladder inflammation, or gallbladder surgery?

Gallstones and cholecystitis, which means an inflamed gallbladder, appear in the label because gallbladder events occurred in weight-management trials. The history helps the provider separate a familiar symptom from a new concern and decide what monitoring makes sense. It doesn't create an automatic answer by itself.

4. How are my kidneys, and do I get dehydrated easily?

Tirzepatide isn't described as directly toxic to the kidneys. The concern is the chain reaction: nausea, vomiting, or diarrhea can reduce fluid in the body, and that can cause acute kidney injury, meaning a sudden drop in kidney function. Recent kidney results and any history of dehydration give the provider a safer starting point.

Medicines, pregnancy plans, and food

5. Do I have diabetes, take insulin or a sulfonylurea, or have diabetic eye disease?

Insulin and sulfonylureas, a group of diabetes pills that increase insulin release, can push blood sugar too low when combined with tirzepatide. The provider may need to coordinate doses and glucose checks.

As of September 9, 2026, the day this article was written, the Zepbound prescribing information, revised August 2026, also says rapid improvement in glucose can temporarily worsen diabetic retinopathy, which is damage to the retina at the back of the eye. That makes past eye treatment or vision changes part of the intake, not a side note.

6. Could pregnancy be part of my plans, and do I use an oral contraceptive?

The label says treatment is discontinued when pregnancy is recognized because weight loss offers no benefit during pregnancy and human safety data are insufficient. It can also delay stomach emptying enough to reduce the effectiveness of birth-control pills after treatment begins and after a dose increase. The prescriber can help build a contraception or preconception plan around the actual timeline.

7. Am I taking another GLP-1 or weight-management medicine?

That list includes prescriptions, over-the-counter products, injections, and supplements. Semaglutide is another GLP-1 medicine. The Zepbound label says using it with another tirzepatide product or any GLP-1 receptor agonist isn't recommended. Naming every product prevents accidental overlap and gives the provider a clean view of what has or hasn't been tolerated.

Digestion and the way eating feels

8. Have I had gastroparesis or another severe digestive condition?

Gastroparesis means the stomach empties unusually slowly. Tirzepatide slows stomach emptying too, and the label doesn't recommend Zepbound for severe gastroparesis. Ordinary constipation isn't the same diagnosis. The useful history is specific: prior testing, repeated vomiting, bowel obstruction, severe constipation, or trouble keeping food and fluids down.

9. Do I have a current or past eating disorder?

An eating-disorder history isn't listed as a formal contraindication in the Zepbound label. It still changes the review because tirzepatide affects hunger, fullness, and food intake. The provider may want input from a mental-health or eating-disorder clinician, a nutrition plan, or a different approach. The point is support and context, not judgment.

The SURMOUNT-1 trial of 2,539 adults helps explain why the stomach questions are detailed: gastrointestinal events were the most common side effects, usually mild to moderate and concentrated while doses were rising. The site's fuller tirzepatide side-effects guide owns those numbers and what they can feel like.

One calendar question people miss

10. Is any surgery or procedure with anesthesia coming up?

Tirzepatide delays stomach emptying. The label records rare reports of pulmonary aspiration, when stomach contents enter the lungs, during general anesthesia or deep sedation even after reported fasting. It also says the evidence isn't sufficient to set one universal stopping or fasting plan. That is why the prescriber, surgeon, and anesthesia team need the same medication timeline.

Questions to ask back before the visit ends

A good review works both ways. Three questions make the care arrangement much clearer:

  • What happens if I don't qualify? A useful answer explains whether the concern is a firm contraindication, missing information, or something that needs another clinician's input.
  • How does follow-up work? The useful details are who handles side effects, how dose decisions are made, and what kind of change prompts a message.
  • What will the pharmacy label say? A complete answer identifies the patient, prescribed directions, dispensing pharmacy, concentration, beyond-use date, and storage instructions. It also makes clear whether the medicine is branded or compounded.

For the visit process itself—from intake through provider review and dispensing—see what to expect from your first visit.

What the answers decide

Promise's tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. The pharmacy label and the provider's directions, not a brand label or an online schedule, govern the actual prescription.

A licensed provider reviews every request, and not everyone qualifies.